Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Project: Clinical Trial

Project Details

StatusActive
Effective start/end date3/24/20 → …